Sean Scanlan - Jan 10, 2024 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Chief Innovation Officer
Signature
/s/ Lisa Taylor as Attorney-in-fact for Sean Scanlan
Stock symbol
TMCI
Transactions as of
Jan 10, 2024
Transactions value $
$0
Form type
4
Date filed
1/12/2024, 09:00 PM
Previous filing
Nov 3, 2023
Next filing
Mar 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Award $0 +65K +202.04% $0.00 97.2K Jan 10, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMCI Stock Option (Right to Buy) Award $0 +73.2K $0.00 73.2K Jan 10, 2024 Stock Option (Right to Buy) 73.2K $13.46 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 10, 2025 and the last installment vesting on January 10, 2028; subject to Reporting Person's providing continued service to Issuer through each vesting date.
F2 Includes 96,070 RSUs.
F3 The stock option vests in equal annual installments over 4 years, with the first installment vesting on January 10, 2025 and the last installment vesting on January 10, 2028, subject to Reporting Person's providing continued service to Issuer through each vesting date.